On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic information.
Frontiers in immunology
View this publicationFrontiers in immunology
View this publicationFrontiers in oncology
View this publicationExperimental hematology
View this publicationCancers
View this publicationRheumatology international
View this publicationBlood cancer journal
View this publicationTrends in cancer
View this publicationFrontiers in oncology
View this publicationFrontiers in immunology
View this publicationAnnals of hematology
View this publication